0001567619-21-019063.txt : 20211101
0001567619-21-019063.hdr.sgml : 20211101
20211101142002
ACCESSION NUMBER: 0001567619-21-019063
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211029
FILED AS OF DATE: 20211101
DATE AS OF CHANGE: 20211101
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Innoviva, Inc.
CENTRAL INDEX KEY: 0001080014
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37544
FILM NUMBER: 211366570
BUSINESS ADDRESS:
STREET 1: 1350 OLD BAYSHORE HIGHWAY
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: 6502389600
MAIL ADDRESS:
STREET 1: 1350 OLD BAYSHORE HIGHWAY
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
FORMER NAME:
FORMER CONFORMED NAME: THERAVANCE INC
DATE OF NAME CHANGE: 20020207
FORMER NAME:
FORMER CONFORMED NAME: ADVANCED MEDICINE INC
DATE OF NAME CHANGE: 20000302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Innoviva Strategic Opportunities LLC
CENTRAL INDEX KEY: 0001842875
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37544
FILM NUMBER: 211366569
BUSINESS ADDRESS:
STREET 1: 1209 ORANGE STREET
CITY: WILMINGTON
STATE: DE
ZIP: 19801
BUSINESS PHONE: 877 202 1097
MAIL ADDRESS:
STREET 1: 1209 ORANGE STREET
CITY: WILMINGTON
STATE: DE
ZIP: 19801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Armata Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0000921114
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 911549568
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4503 GLENCOE AVENUE
CITY: MARINA DEL REY
STATE: CA
ZIP: 90292
BUSINESS PHONE: 310-665-2928
MAIL ADDRESS:
STREET 1: 4503 GLENCOE AVENUE
CITY: MARINA DEL REY
STATE: CA
ZIP: 90292
FORMER COMPANY:
FORMER CONFORMED NAME: AmpliPhi Biosciences Corp
DATE OF NAME CHANGE: 20130222
FORMER COMPANY:
FORMER CONFORMED NAME: TARGETED GENETICS CORP /WA/
DATE OF NAME CHANGE: 19940331
4
1
doc1.xml
FORM 4
X0306
4
2021-10-29
0
0000921114
Armata Pharmaceuticals, Inc.
ARMP
0001080014
Innoviva, Inc.
1350 OLD BAYSHORE HIGHWAY SUITE 400
BURLINGAME
CA
94010
1
0
1
0
0001842875
Innoviva Strategic Opportunities LLC
1350 OLD BAYSHORE HIGHWAY SUITE 400
BURLINGAME
CA
94010
1
0
1
0
Common Stock
2021-10-29
4
P
0
1212122
3.30
A
7365969
I
See footnotes
Common Stock
8710800
D
On October 28, 2021, Innoviva Strategic Opportunities LLC ("Innoviva Sub"), a Delaware limited liability company and a wholly-owned subsidiary of Innoviva, Inc. ("Innoviva" and, together with Innoviva Sub, the "Reporting Persons"), entered into that certain Securities Purchase Agreement (the "Purchase Agreement") with Armata Pharmaceuticals, Inc., a Washington corporation (the "Issuer") and another purchaser, pursuant to which, on October 29, 2021 Innoviva Sub acquired 1,212,122 newly issued shares of common stock, $0.01 par value per share, of the Issuer ("Common Stock"). In addition, pursuant to previous transactions, (i) Innoviva Sub is the direct beneficial owner, and Innoviva is the indirect beneficial owner, of an additional 6,153,847 shares of Common Stock and (ii) Innoviva is the direct beneficial owner of 8,710,800 shares of Common Stock.
In 2020, Innoviva designated Odysseas Kostas, M.D. and in 2021, Innoviva designated Jules Haimovitz, two of the members of the board of directors of Innoviva, to serve on the board of directors of the Issuer. As such, solely for purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization. For purposes of the exemption under Rule 16b-3 promulgated under the Exchange Act, the board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any shares of Common Stock, as a result of or in connection with the transactions reported on this Form 4.
INNOVIVA, INC., by /s/ Pavel Raifeld
2021-11-01
INNOVIVA STRATEGIC OPPORTUNITIES LLC, by Innoviva, Inc., its managing member, /s/ Pavel Raifeld
2021-11-01